Lung cancer is one of the most frequently diagnosed cancers and the leading cause of cancer-related deaths worldwide with an estimated 2 million new cases and 1·76 million deaths per year. Substantial ...

CX compounds identified from pharmacophore modeling inhibited cell migration, lung and colon cancer cell proliferation, and colony formation. Mechanistic studies of CX4152 showed that this compound ...

Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to ...

To Joshua Bauml, vice president, lung cancer area stronghold leader at J&J, the company’s experience in multiple myeloma is a blueprint for its strategy in lung cancer. “Look at what we’ve ...

"I think we've moved the needle in extensive-stage small cell [lung cancer] more in the last 3 hours than we have in the last 30 years." Langer, who was not involved in the studies, added a ...

According to Rachael A. Safyan, MD, medical director of the Fred Hutch/UW Medicine HAI Pump Program, HAI is primarily for patients with metastatic colorectal cancer that has spread to the liver. Early ...

The median overall survival was 13.6 months in the tarlatamab arm and 8.3 months in the chemotherapy arm. Second-line treatment with tarlatamab improves progression-free survival (PFS) and overall ...

People are more likely to get cancer as they age. Dr. Miriam Merad has an unconventional idea of how that might be reversed: using allergy drugs and other seemingly unlikely medications to damp a ...

Ivonescimab is now in multiple Phase III trials for different forms of lung cancer, and Summit plans to submit an application for FDA approval by the end of the year. It can’t come too soon.

Eating food that lowers inflammation in the body may help people with advanced colon cancer survive longer, according to research presented at a meeting of the American Society of Clinical ...

to find pancreatic cancer cell lines that had a tendency to colonize either the lung or the liver. Then, they looked for genomic differences that could reveal why, or even how, these cells ...

J. Randolph (Randy) Hecht, MD, discusses the phase 3 OrigAMI-3 trial for patients with recurrent, unresectable, or metastatic RAS/BRAF wild-type colorectal cancer. J. Randolph (Randy) Hecht, MD, ...